Biocon has approved the appointment of Peter Bains as the Group CEO, with effect from September 18, 2023. He will be reporting directly to Biocon Group Chairperson, Kiran Mazumdar-Shaw.
Bains has accordingly stepped down from his role on the Biocon Board as an Independent Director with immediate effect, to assume this strategic executive responsibility.
Welcoming this appointment, Mazumdar-Shaw said, “Biocon is entering a dynamic phase of growth for its three core businesses, Biocon Biologics, Biocon Generics and Syngene, and for the Group as a whole. I am delighted to welcome Peter back to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD, Biocon, Shreehas Tambe, CEO & MD Biocon Biologics and Jonathan Hunt, CEO & MD, Syngene International will continue to have independent charge of their businesses and will work with Peter to strengthen synergistic strategic leadership at a Group level to maximise the combined value of all three businesses. Peter has a unique fit and profile for the role having both extensive global leadership experience and success across the biopharmaceutical field and a comprehensive understanding of the Biocon Group, having led Syngene for five years, taking it through its very successful IPO in 2015. I am confident that this appointment will serve the integrated business objectives of the Biocon Group of companies and deliver added value to all stakeholders.”